A Study Comparing Shared Solutions® Plus MS Center Support Versus Shared Solutions® Alone
NCT ID: NCT00240006
Last Updated: 2011-04-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
307 participants
INTERVENTIONAL
2006-01-31
2007-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple Sclerosis
NCT00203086
A Study to Evaluate Readiness to Self-inject on Adherence and Compliance to Copaxone® Therapy
NCT00238654
Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis
NCT00219908
A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.
NCT00203073
Development of a Motivational Intervention to Improve Treatment Adherence in MS
NCT01925690
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Shared Solutions®
Shared Solutions® plus MS Center v. Shared Solutions®
Copaxone
2
Shared Solutions® and MS Center/Office Practice Partnership
Shared Solutions® plus MS Center v. Shared Solutions®
Copaxone
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Shared Solutions® plus MS Center v. Shared Solutions®
Copaxone
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Diagnosed with Relapsing Remitting Multiple Sclerosis (relapses accepted).
3. Beginning or restarting therapy with Glatiramer Acetate (Copaxone®).
4. Willing and able to complete all procedures and evaluations related to the study.
5. Willing to provide informed consent.
Exclusion Criteria
2. Has a significant medical illness other than MS that may interfere with the assessment of endpoints or the subject's participation in the trial for the full duration of the study.
3. Any situation that the investigator or nurse (if not the investigator) feel may interfere with participation in the study.
4. Pregnant or trying to become pregnant, or breast feeding during the study.
5. Previously participated in this study or another clinical research study in the past 30 days.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Teva Neuroscience, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Teva Neuroscience
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MerriKay Oleen-Burkey, Ph.D.
Role: STUDY_DIRECTOR
Teva Neuroscience, Inc.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PM024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.